ARS Pharmaceuticals Reports 184% Revenue Growth to $22.7 Million, Despite Increased Net Loss

ARS Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenue of $22.7 million, a substantial increase of 184% compared to $8.0 million in the same period last year. This growth was primarily driven by product revenue from neffy, which amounted to $17.5 million, reflecting a 125% increase from $7.8 million in the prior year. Additionally, the company recognized $2.5 million in revenue from collaboration agreements and $2.7 million from supply agreements, marking a notable expansion in its revenue streams.

Despite the revenue growth, ARS Pharmaceuticals reported a net loss of $60.6 million for the first quarter of 2026, up from a loss of $33.9 million in the same quarter of 2025. The increase in losses was attributed to a rise in operating expenses, which totaled $82.8 million, compared to $45.2 million in the previous year. The increase in expenses was largely driven by selling, general, and administrative costs, which surged to $72.2 million from $41.1 million, reflecting the company's investment in marketing and sales efforts to support the launch of neffy.

Operationally, ARS Pharmaceuticals has made significant strides in expanding its market presence. As of March 31, 2026, approximately 120,000 patients were using neffy in the U.S., with 28,000 healthcare providers having prescribed the product. The company has achieved approximately 90% overall commercial coverage, with 57% of commercial insurance plans covering neffy without prior authorization. The company’s sales force has also expanded to 148 employees, bolstered by a co-promotion agreement with ALK U.S., which began in June 2025.

Looking ahead, ARS Pharmaceuticals remains focused on leveraging its recent product launches and expanding its market share in the epinephrine delivery space. The company has received regulatory approvals for neffy in multiple international markets, including the EU, Japan, Australia, and Canada, and is actively pursuing additional approvals. However, the company continues to face challenges, including the need for ongoing funding to support its operations and the potential impact of competitive products in the market. As of March 31, 2026, ARS Pharmaceuticals had cash, cash equivalents, and short-term investments totaling $201 million, which it believes will be sufficient to meet its anticipated cash requirements for at least the next 12 months.